5.205
price down icon7.88%   -0.445
 
loading
Schlusskurs vom Vortag:
$5.65
Offen:
$5.65
24-Stunden-Volumen:
28,644
Relative Volume:
0.33
Marktkapitalisierung:
$2.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+1.88%
1M Leistung:
+6.55%
6M Leistung:
-67.67%
1J Leistung:
-97.11%
1-Tages-Spanne:
Value
$5.11
$5.69
1-Wochen-Bereich:
Value
$4.91
$5.69
52-Wochen-Spanne:
Value
$2.9218
$699.19

Psyence Biomedical Ltd Stock (PBM) Company Profile

Name
Firmenname
Psyence Biomedical Ltd
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
10
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
PBM's Discussions on Twitter

Vergleichen Sie PBM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PBM
Psyence Biomedical Ltd
5.205 2.90M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Psyence Biomedical Ltd Aktie (PBM) Neueste Nachrichten

pulisher
Jun 18, 2025

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 - TradingView

Jun 18, 2025
pulisher
Jun 18, 2025

Psychedelic Industry Summit: Top CEOs and Investors Unite to Shape $Billion Market Future - Stock Titan

Jun 18, 2025
pulisher
Jun 17, 2025

Psyence Biomedical regains Nasdaq compliance after reverse split By Investing.com - Investing.com Nigeria

Jun 17, 2025
pulisher
Jun 17, 2025

Psyence Biomedical regains Nasdaq compliance after reverse split - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements - Newsfile

Jun 17, 2025
pulisher
Jun 14, 2025

Psyence Biomedical (NASDAQ:PBM) Upgraded by Wall Street Zen to “Hold” Rating - Defense World

Jun 14, 2025
pulisher
Jun 11, 2025

Psyence Biomedical Advances Psilocybin Trial with New CRO Agreement - TipRanks

Jun 11, 2025
pulisher
Jun 03, 2025

Psyence Biomedical Ltd. (NASDAQ:PBM) Short Interest Up 55.3% in May - Defense World

Jun 03, 2025
pulisher
May 27, 2025

Psyence BioMed advances Phase IIb psilocybin trial with new CRO partnershi By Investing.com - Investing.com South Africa

May 27, 2025
pulisher
May 27, 2025

Psyence BioMed advances Phase IIb psilocybin trial with new CRO partnershi - Investing.com Australia

May 27, 2025
pulisher
May 27, 2025

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial - TradingView

May 27, 2025
pulisher
May 27, 2025

FDA Backs Psyence BioMed's Groundbreaking Phase IIb Psilocybin Trial for Cancer Mental Health - Stock Titan

May 27, 2025
pulisher
May 27, 2025

Psyence Biomedical (NASDAQ:PBM) Shares Down 0.7% – Should You Sell? - Defense World

May 27, 2025
pulisher
May 20, 2025

Psyence Biomedical Advances Psilocybin Drug Development as of May 2025 - TipRanks

May 20, 2025
pulisher
May 08, 2025

Reviewing Psyence Biomedical (NASDAQ:PBM) and Immunic (NASDAQ:IMUX) - Defense World

May 08, 2025
pulisher
May 02, 2025

Psyence Biomedical announces reverse stock split - Investing.com

May 02, 2025
pulisher
May 01, 2025

Psyence Biomedical announces reverse stock split By Investing.com - Investing.com Nigeria

May 01, 2025
pulisher
May 01, 2025

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split - Newsfile

May 01, 2025
pulisher
May 01, 2025

Psyence BioMed Reverse Split Cuts 4.6M Shares to 583K: What Investors Must Know Before May 5 - Stock Titan

May 01, 2025
pulisher
Apr 23, 2025

Psyence Biomedical Faces Nasdaq Delisting Amid Shareholder Approval for Reverse Stock Split - TipRanks

Apr 23, 2025
pulisher
Apr 20, 2025

Psyence BioMed gets Nasdaq notice for non-compliance - MSN

Apr 20, 2025
pulisher
Apr 18, 2025

Psyence Group consolidates its shares - Crain's Chicago Business

Apr 18, 2025
pulisher
Apr 17, 2025

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - TradingView

Apr 17, 2025
pulisher
Apr 17, 2025

Psyence BioMed Under Nasdaq Delisting Pressure: Key Details About the 1:7.97 Reverse Split Solution - Stock Titan

Apr 17, 2025
pulisher
Apr 16, 2025

Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine

Apr 16, 2025
pulisher
Apr 15, 2025

Psyence BioMed boosts stake in PsyLabs with $500k investment By Investing.com - Investing.com Nigeria

Apr 15, 2025
pulisher
Apr 15, 2025

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement - Newsfile

Apr 15, 2025
pulisher
Apr 11, 2025

Psyence Biomedical Transitions CRO for Psilocybin Trial in April 2025 - TipRanks

Apr 11, 2025
pulisher
Apr 08, 2025

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia - Newsfile

Apr 08, 2025
pulisher
Apr 08, 2025

Major Expansion: Psyence's Breakthrough Cancer Mental Health Trial Targets Untreated Disorder - Stock Titan

Apr 08, 2025
pulisher
Apr 02, 2025

Psyence Biomedical reports corporate update By Investing.com - Investing.com Australia

Apr 02, 2025
pulisher
Apr 01, 2025

Psyence Biomedical reports corporate update - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Psyence BioMed Advances in Psychedelic Medicine with Strategic Growth and Clinical Trials - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Psyence Biomedical Announces Special Shareholder Meeting for Share Consolidation - TipRanks

Mar 31, 2025
pulisher
Mar 25, 2025

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein - The Manila Times

Mar 25, 2025
pulisher
Mar 21, 2025

Psyence Biomedical Ltd. (NASDAQ:PBMWW) Short Interest Down 13.1% in February - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

Psyence Biomed expands advisory board with psychopharmacology expert By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Psyence Biomed expands advisory board with psychopharmacology expert - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein - Newsfile

Mar 18, 2025
pulisher
Mar 18, 2025

Top Columbia Psychiatrist Joins Psyence's Psilocybin Clinical Trial Team - StockTitan

Mar 18, 2025
pulisher
Mar 10, 2025

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - The Manila Times

Mar 10, 2025

Finanzdaten der Psyence Biomedical Ltd-Aktie (PBM)

Es liegen keine Finanzdaten für Psyence Biomedical Ltd (PBM) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Kapitalisierung:     |  Volumen (24h):